Archeoptix Biomedical

Portable Imaging for TBI with CT Precision

Archeoptix Biomedical Inc. has developed a portable imager that provides CT precision in determining the severity of Traumatic Brain Injury (TBI) and other causes of brain bleeds (Stroke in particular – distinguishing hemorrhagic vs. ischemic stroke). Our technologies have the potential to change the way TBI (and Stroke) is managed globally. TBI is the single largest healthcare cost in the modern world, with 69 million affected globally every year. We have a strong and experienced team, and we have a very strong IP portfolio.

TBI is a major global health issue, affecting 69 million people annually and leading to significant costs. It is a leading cause of death for children and particularly impacts individuals under 45. Furthermore, an aging population with increased susceptibility to falls will likely compound the prevalence and impact of TBI in the coming years.

Archeoptix has developed the NIRD®, a lightweight, portable device that provides CT accuracy in determining the severity of Traumatic Brain Injury (TBI) and other causes of brain bleeds. It is not a replacement for CT—we bring CT capabilities to the point of injury, where it matters most.

The NIRD® weighs 8.5 lbs, is non-invasive, emits no radiation, and provides valuable information about other conditions, including hemorrhagic and ischemic stroke. Like no other TBI device/technology in the world, the NIRD® provides imaging that can be used by healthcare professionals with different levels of experience/training.

The NIRD® offers a solution to front-line healthcare workers by accurately detecting 95-98% of acute subdural and epidural hematomas, the most common TBI hemorrhages. This portable, easy-to-use device allows for rapid assessment and can be used in various settings, improving patient outcomes and reducing healthcare costs.

Our mission is driven by a team of visionary leaders at the forefront of innovation. With a diverse blend of expertise spanning technology, neuroscience, agrochemicals and biotech, our leadership team brings unparalleled dedication and ingenuity to every aspect of our work. Get to know the dynamic individuals shaping the future of TBI management and discover the passion and expertise fuelling our groundbreaking solutions.

Sav  Stratis

Sav Stratis

  • Chief Executive Officer (CEO)
Jason  Riley

Jason Riley

  • CTO: Chief Technology Officer